Toshiaki Tanaka1, Takahiro Sato2, Akira Yuasa Mhwm3, Takeshi Akiyama4, Adeeb Tawseef4. 1. Tanaka Growth Clinic, Tokyo, Japan. 2. Medical Affairs, Rare Disease, Pfizer Japan Inc, Tokyo, Japan. 3. Corporate Affairs, Health and Value, Pfizer Japan Inc, Tokyo, Japan. 4. Takeshi Akiyama & Adeeb Tawseef, IQVIA Solutions Japan K.K, RWE & HEOR, Tokyo, Japan.
Abstract
BACKGROUND: There are no any clear evidence to date has evaluating patients' and caregiver' preferences for r-hGH (recombinant-human growth hormone) injection in children in Japan. This study quantitatively evaluated the factors driving preferences for daily r-hGH injection among Japanese children with Growth Hormone Deficiency (GHD) or their caregivers and to determine the relative importance of treatment delivery attributes. METHODS: This study was performed among Japanese children with GHD or their caregivers who visited a specialized clinic in Japan as part of their routine care. The participants were asked to complete a web-based discrete choice experiment (DCE) questionnaire. RESULTS: Choice-based conjoint analysis was used to evaluate the relative importance of attributes as choice predictors and determine utilities for each attribute. Of the 47 respondents who participated in this study, 41 were caregivers who responded on behalf of the patients, and the remaining 6 were patients who completed the DCE themselves. The injection schedule was found to be the most important attribute for both patients and caregivers; a once-weekly injection schedule was preferred over a daily injection schedule. The storage and preparation attribute was deemed more important to patients than it was to caregivers, with patients preferring store in room temperature even if it needed an additional mixing(reconstitution) step. Both patients and caregivers showed a clear preference for devices that offered a dose setting memory. CONCLUSIONS: A less frequent injection schedule may enhance adherence to r-hGH treatment, and expected improve quality of life in GHD patients over the long term. This article is protected by copyright. All rights reserved.
BACKGROUND: There are no any clear evidence to date has evaluating patients' and caregiver' preferences for r-hGH (recombinant-humangrowth hormone) injection in children in Japan. This study quantitatively evaluated the factors driving preferences for daily r-hGH injection among Japanese children with Growth Hormone Deficiency (GHD) or their caregivers and to determine the relative importance of treatment delivery attributes. METHODS: This study was performed among Japanese children with GHD or their caregivers who visited a specialized clinic in Japan as part of their routine care. The participants were asked to complete a web-based discrete choice experiment (DCE) questionnaire. RESULTS: Choice-based conjoint analysis was used to evaluate the relative importance of attributes as choice predictors and determine utilities for each attribute. Of the 47 respondents who participated in this study, 41 were caregivers who responded on behalf of the patients, and the remaining 6 were patients who completed the DCE themselves. The injection schedule was found to be the most important attribute for both patients and caregivers; a once-weekly injection schedule was preferred over a daily injection schedule. The storage and preparation attribute was deemed more important to patients than it was to caregivers, with patients preferring store in room temperature even if it needed an additional mixing(reconstitution) step. Both patients and caregivers showed a clear preference for devices that offered a dose setting memory. CONCLUSIONS: A less frequent injection schedule may enhance adherence to r-hGH treatment, and expected improve quality of life in GHD patients over the long term. This article is protected by copyright. All rights reserved.
Authors: Aristides K Maniatis; Mauri Carakushansky; Sonya Galcheva; Gnanagurudasan Prakasam; Larry A Fox; Adriana Dankovcikova; Jane Loftus; Andrew A Palladino; Maria de Los Angeles Resa; Carrie Turich Taylor; Mehul T Dattani; Jan Lebl Journal: J Endocr Soc Date: 2022-09-10